Korro Bio
KRRO
82 hedge funds and large institutions have $95M invested in Korro Bio in 2021 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 17 increasing their positions, 33 reducing their positions, and 25 closing their positions.
264% more call options, than puts
Call options by funds: $579K | Put options by funds: $159K
0.06% less ownership
Funds ownership: 1.09% → 1.02% (-0.06%)
7% less funds holding
Funds holding: 88 → 82 (-6)
24% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 25
30% less capital invested
Capital invested by funds: $135M → $95M (-$39.8M)
48% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 33
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$1.93M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$1.39M |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$841K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$539K |
| 5 |
LOAMS
Lombard Odier Asset Management (Switzerland)
Petit-Lancy,
Switzerland
|
+$364K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$2M |
| 2 |
PA
Perceptive Advisors
New York
|
-$1.57M |
| 3 |
Stifel Financial
St. Louis,
Missouri
|
-$1.42M |
| 4 |
BlackRock
New York
|
-$893K |
| 5 |
Two Sigma Investments
New York
|
-$893K |
KRRO Hedge Fund Activity: Q4 2021 in Review
82 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Korro Bio (KRRO) for Q4 2021, worth a combined $95M — down 30% from $135M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of KRRO and 19 opened new positions — a net loss of 6 holders — while 33 trimmed existing stakes and 17 added.
The largest buyer was Jacobs Levy Equity Management, opening a new position worth an estimated $1.93M. The largest seller was Morgan Stanley, cutting an estimated $2M.
- 82 institutional investors held Korro Bio (KRRO) as of Q4 2021, down from 88 in Q3 2021.
- Funds reported $95M of Korro Bio stock for Q4 2021, down 30% quarter-over-quarter.
- 19 funds opened new Korro Bio positions in Q4 2021 and 25 closed out, a net change of -6 holders.
- The largest Korro Bio buyer in Q4 2021 was Jacobs Levy Equity Management, an estimated $1.93M added.
- The largest Korro Bio seller in Q4 2021 was Morgan Stanley, an estimated $2M sold.
Based on aggregated 13F filings for Q4 2021.